STOCKHOLM, December 6, 2021 / PRNewswire / – XNK Therapeutics AB (“XNK”) today announced that it will conduct a proof of concept study in acute myeloid leukemia (AML) using patient samples from The University of Texas MD Anderson Cancer Center.
The proof of concept study involves determining the feasibility of expanding and activating NK cells from AML patients using XNK’s proprietary platform. The objective is to establish patient selection criteria for a clinical trial using the XNK platform and, ultimately, to develop new therapeutic approaches for patients with AML.
“Autologous treatments have a number of advantages. For example, they do not require pre-conditioning, which can reduce the risk of serious infections, while potentially offering a persistent response,” said Michael uhlin, CSO of XNK Therapeutics.
AML is a type of cancer in which the bone marrow makes a large number of abnormal blood cells. Leukemia can affect red blood cells, white blood cells and platelets. In 2021, there will be around 20,240 new cases of AML and 11,400 deaths in the United States alone, according to the American Cancer Society.
“XNK is currently active in the clinical development and manufacture of autologous natural killer cell products using its proprietary technology platform,” said Johan Liwing, CEO of XNK Therapeutics. “XNK has promising clinical data in multiple myeloma and the scientific rationale for the application of XNK’s technology in other indications, including hematologic and solid cancers, is strong. “
For more information please contact:
Johan Liwing, CEO, XNK Therapeutics
Phone. : +46 706 70 36 75
E-mail: [email protected]
About XNK Therapeutics AB
XNK Therapeutics is a clinical-stage immunotherapy company focused on the prevention and treatment of cancer by developing novel therapies based on NK cells. The company is at the forefront of development of autologous NK cell products using its proprietary technology platform. The company’s technology platform and leading research drug candidate have been developed specifically to target cancers, including settings where allogeneic cell products are not readily applicable. The Company’s objective is for its experimental drug candidate and its proprietary technological platform to constitute key components of future cancer treatments. XNK Therapeutics is headquartered at Stockholm, Sweden. For more information, please visit www.xnktherapeutics.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE XNK Therapeutics AB